Creatine Kinase MB Type II

<strong>Creatine Kinase MB Type II</strong>_x000D_ <strong>Catalog number:</strong> B2012161_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 250 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 84 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> r-hCKMB II, r-hCK-MB, r-hCK-2_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, Johnston TP, Sahebkar A. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up Expert Rev Anti Infect Ther. 2021 Mar;19(3):345-357._x000D_ 2: Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC. Selumetinib in Children with Inoperable Plexiform Neurofibromas N Engl J Med. 2020 Apr 9;382(15):1430-1442._x000D_ 3: Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):682-689._x000D_ 4: Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS; ISCHEMIA Research Group. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons Circulation. 2021 Feb 23;143(8):790-804._x000D_ 5: Schreuder AB, Rossi A, Grünert SC, Derks TGJ. Glycogen Storage Disease Type III 2010 Mar 9 [updated 2022 Jan 6]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022._x000D_ 6: Habte ML, Melka DS, Degef M, Menon MKC, Yifter H, Feyisa TO. Comparison of Lipid Profile, Liver Enzymes, Creatine Kinase and Lactate Dehydrogenase Among Type II Diabetes Mellitus Patients on Statin Therapy Diabetes Metab Syndr Obes. 2020 Mar 18;13:763-773._x000D_ 7: Jansson E, Sylvén C. Creatine kinase MB and citrate synthase in type I and type II muscle fibres in trained and untrained men Eur J Appl Physiol Occup Physiol. 1985;54(2):207-9._x000D_ 8: Irmak K, Tüten N, Karaoglu G, Madazli R, Tüten A, Malik E, Güralp O. Evaluation of cord blood creatine kinase (CK), cardiac troponin T (cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), and s100B levels in nonreassuring foetal heart rate J Matern Fetal Neonatal Med. 2021 Apr;34(8):1249-1254._x000D_ 9: Zbierska-Rubinkiewicz K, Trębacz O, Tomala M, Rubinkiewicz M, Chrzan I, Gackowski A. Creatine kinase-MB and red cell distribution width as predictors of contrast-induced nephropathy after percutaneous coronary intervention in acute myocardial infarction Folia Med Cracov. 2017;57(3):87-99._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32821600">10: Pillai B, Trikkur S, Farooque U, Ramakrishnan D, Kakkra JJ, Kashyap G, Lalwani C, Mani AB, Vishwanath J. Type II Myocardial Infarction: Predisposing Factors, Precipitating Elements, and Outcomes Cureus. 2020 Jul 18;12(7):e9254. </a>_x000D_ _x000D_ <strong>Products Related to Creatine Kinase MB Type II can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>